



University of Southern Denmark

**A Multicenter Randomized Controlled Trial comparing [18F]PSMA-1007-PET/CT with Conventional Imaging in Primary Staging of Prostate Cancer (Vinder af posterprisen)  
PRISMA-PET**

Buch-Olsen, Karen M; Vilstrup, Mie Holm; Hansen, Steinbjørn; Hess, Søren; Holdgaard, Paw Christian; Poulsen, Mads Hvid; Dam, Johan Hygum; Sørensen Madsen, Søren; Hildebrandt, Malene Grubbe

*Publication date:*  
2021

*Document version:*  
Final published version

*Citation for pulished version (APA):*

Buch-Olsen, K. M., Vilstrup, M. H., Hansen, S., Hess, S., Holdgaard, P. C., Poulsen, M. H., Dam, J. H., Sørensen Madsen, S., & Hildebrandt, M. G. (2021). *A Multicenter Randomized Controlled Trial comparing [18F]PSMA-1007-PET/CT with Conventional Imaging in Primary Staging of Prostate Cancer (Vinder af posterprisen): PRISMA-PET*. Abstract from Dansk Selskab for Klinisk Fysiologi og Nuklearmedicins Årsmøde 2021, Aalborg, Denmark.

Go to publication entry in University of Southern Denmark's Research Portal

**Terms of use**

This work is brought to you by the University of Southern Denmark.  
Unless otherwise specified it has been shared according to the terms for self-archiving.  
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.  
Please direct all enquiries to [puresupport@bib.sdu.dk](mailto:puresupport@bib.sdu.dk)

# A Multicenter Randomized Controlled Trial comparing [18F]PSMA-1007-PET/CT with Conventional Imaging in Primary Staging of Prostate Cancer.


Authors: K. M. Buch-Olsen, M. H. Vilstrup, S. Hansen, S. Hess, P. C. Holdgaard, M. H. Poulsen, J. H. Dam, S. S. Madsen, M. G. Hildebrandt.

Departments of Nuclear Medicine, Urology and Oncology in Region of Southern Denmark.

## Aim

This study aims to evaluate the impact on treatment strategy, progression-free survival and quality of life of staging primary Prostate Cancer patients with PSMA-PET/CT.

EudraCT number 2021-000123-12



### Inclusion criteria

- Biopsy verified prostate cancer **AND**
- PSA  $\geq$  20 ng/ml **OR**
- Gleason Score  $\geq$  4+3 **OR**
- Tumor stage cT2c or above **OR**
- Staging by imaging warranted due to suspicion of metastases


### Primary endpoints (A vs. B)

- Choice of Treatment
- Progression free survival
- Quality of life


### Secondary endpoints:

- Overall survival (A vs. B)
- Accuracy (NaF vs. PSMA, bone)

Soon visible on [clinicaltrials.gov](https://clinicaltrials.gov)



The PSMA-PET/CT shows marked uptake in this 6 mm lymph node, suspicious for a metastasis.



Patient recruitment from all centers in the Region of Southern Denmark

kmbo@rsyd.dk – Nothing to disclose